Hepatitis A, B, and C

  • Jonathan Merola
  • Alexander Z. Jow
  • Samuel H. SigalEmail author


Viral hepatitis remains the leading cause of liver failure and is the primary indication for liver transplantation worldwide. Hepatitis viruses are categorized into five distinct subtypes that collectively render significant morbidity and mortality in transplanted patients. Each subtype has a distinct replication pattern, pathology, and treatment. While the primary pathology mediated by these viruses occurs within the liver, significant extrahepatic disease may be observed with particular subtypes of hepatitis and warrant special treatment modalities prior to and following transplantation. Advances in the management of hepatitis B and C have recently revolutionized the treatment paradigm from supportive care to cure. In this section, each hepatitis subtype is described separately and accompanied by diagnostic and treatment strategies with emphasis on care for the transplanted patient.


Transplant Liver Hepatitis A virus Hepatitis B virus Hepatitis C virus Antiviral therapy 


  1. 1.
    Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L, Hepatitis A. Epidemiology and prevention in developing countries. World J Hepatol. 2012;4(3):68–73.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001;14(1):38–58.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Trepo C, Zoulim F, Pradat P. Viral hepatitis. Curr Opin Infect Dis. 1999;12(5):481–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357(17):1685–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Matheny ME, Fitzhenry F, Speroff T, Green JK, Griffith ML, Vasilevskis EE, et al. Detection of infectious symptoms from VA emergency department and primary care clinical documentation. Int J Med Inform. 2012;81(3):143–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). Hepato-Gastroenterology. 2000;47(33):786–9.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Yoon EL, Yim HJ, Kim SY, Kim JH, Lee JH, Lee YS, et al. Clinical courses after administration of oral corticosteroids in patients with severely cholestatic acute hepatitis A; three cases. Korean J Hepatol. 2010;16(3):329–33.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Attili AF, Rusticali A, Varriale M, Carli L, Repice AM, Callea F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol. 1994;20(3):315–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Keeffe EB. Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases. Trans Am Clin Climatol Assoc. 2006;117:227–37; discussion 37–8PubMedPubMedCentralGoogle Scholar
  10. 10.
    Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338(5):286–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology. 2006;44(6):1589–97.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Arslan M, Wiesner RH, Poterucha JJ, Gross JB Jr, Zein NN. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl. 2000;6(2):191–5.CrossRefGoogle Scholar
  13. 13.
    Eisenbach C, Longerich T, Fickenscher H, Schalasta G, Stremmel W, Encke J. Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A. J Clin Virol. 2006;35(1):109–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Park GC, Hwang S, Yu YD, Park PJ, Choi YI, Song GW, et al. Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation: a case report. Transplant Proc. 2010;42(10):4658–60.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27(3):881–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999;94(6):1601–4.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Brundage SC, Fitzpatrick AN, Hepatitis A. Am Fam Physician. 2006;73(12):2162–8.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Martin K, Drabble A, Manlhiot C, Dipchand AI. Response to hepatitis A and B vaccination after pediatric heart transplant. Pediatr Transplant. 2012;16(7):699–703.CrossRefPubMedGoogle Scholar
  19. 19.
    Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation. 2001;71(3):477–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Unal Ince E, Ertem M, Ileri T, Sayili A, Belgemen T, Uysal Z. Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients. Bone Marrow Transplant. 2010;45(1):171–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int. 2017;11(6):500–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.CrossRefGoogle Scholar
  23. 23.
    Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191–211, vCrossRefPubMedGoogle Scholar
  24. 24.
    Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95(5):755–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49(5 Suppl):S28–34.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996;38(Suppl 2):S18–23.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    LeFevre ML, U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(1):58–66.CrossRefPubMedGoogle Scholar
  28. 28.
    Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292(15):771–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92(6):1844–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77–82.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005;11(7):716–32.CrossRefPubMedGoogle Scholar
  32. 32.
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004;10(8):968–74.CrossRefPubMedGoogle Scholar
  34. 34.
    Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol. 2012;56(5):1189–97.CrossRefPubMedGoogle Scholar
  35. 35.
    Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6(6):741–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528–35.CrossRefPubMedGoogle Scholar
  37. 37.
    Young K, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, et al. Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. J Viral Hepat. 2017;24(9):789–96.CrossRefPubMedGoogle Scholar
  38. 38.
    Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.CrossRefGoogle Scholar
  39. 39.
    Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.CrossRefGoogle Scholar
  40. 40.
    Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38 Suppl 1:84–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47(6):730–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts – a systematic analysis. Clin Transpl. 2011;25(3):E243–9.CrossRefGoogle Scholar
  43. 43.
    Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95(7):960–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Degott C, Degos F, Jungers P, Naret C, Courouce AM, Potet F, et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver. 1983;3(6):377–84.CrossRefPubMedGoogle Scholar
  45. 45.
    Fornairon S, Pol S, Legendre C, Carnot F, Mamzer-Bruneel MF, Brechot C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. 1996;62(2):297–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Raheem OA, Hickey DP. Treatment of hepatitis B virus reactivation in a cadaveric renal transplant recipient with entecavir. Arab J Nephrol Transplant. 2013;6(1):41–4.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Rivolta E, De Vecchi A, Tarantino A, Castelnovo C, Berardinelli L, Ponticelli C. Prognostic significance of hepatitis B surface antigenemia in cadaveric renal transplant patients. Transplant Proc. 1987;19(1 Pt 3):2153–4.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Flagg GL, Silberman H, Takamoto SK, Berne TV. The influence of hepatitis B infection on the outcome of renal allotransplantation. Transplant Proc. 1987;19(1 Pt 3):2155–8.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Huang CC, Lai MK, Fong MT. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation. 1990;49(3):540–4.CrossRefPubMedGoogle Scholar
  50. 50.
    Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29(1):257–63.CrossRefPubMedGoogle Scholar
  51. 51.
    Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5(12):2913–21.CrossRefPubMedGoogle Scholar
  52. 52.
    Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol. 2001;21(4):300–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol. 2011;6(6):1481–7.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transpl. 2002;16(2):130–6.CrossRefGoogle Scholar
  55. 55.
    Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation. 2008;86(6):784–90.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36(5):1246–52.CrossRefPubMedGoogle Scholar
  57. 57.
    Ahn HJ, Kim MS, Kim YS, Kim SI, Huh KH, Ju MK, et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol. 2007;79(11):1655–63.CrossRefPubMedGoogle Scholar
  58. 58.
    Park KS, Yang WS, Han DJ, Park JB, Park JS, Park SK. Long-term impact of prophylactic antiviral treatment in Hepatitis B surface antigen positive renal allograft recipients. Clin Nephrol. 2012;78(4):303–11.CrossRefPubMedGoogle Scholar
  59. 59.
    Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.Google Scholar
  60. 60.
    Daude M, Rostaing L, Saune K, Lavayssiere L, Basse G, Esposito L, et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation. 2011;91(8):916–20.CrossRefPubMedGoogle Scholar
  61. 61.
    Drescher J, Wagner D, Haverich A, Flik J, Stachan-Kunstyr R, Verhagen W, et al. Nosocomial hepatitis B virus infections in cardiac transplant recipients transmitted during transvenous endomyocardial biopsy. J Hosp Infect. 1994;26(2):81–92.CrossRefPubMedGoogle Scholar
  62. 62.
    Wedemeyer H, Pethig K, Manns MP, Boker KH. Hepatitis B infection in heart transplant patients. Gastroenterology. 2001;120(5):1311–3.CrossRefPubMedGoogle Scholar
  63. 63.
    Potthoff A, Tillmann HL, Bara C, Deterding K, Pethig K, Meyer S, et al. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat. 2006;13(11):734–41.CrossRefPubMedGoogle Scholar
  64. 64.
    Wang SS, Chou NK, Ko WJ, Yu HY, Chen YS, Hsu RB, et al. Heart transplantation using donors positive for hepatitis. Transplant Proc. 2004;36(8):2371–3.CrossRefPubMedGoogle Scholar
  65. 65.
    Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997;19(8):795–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Martin BA, Rowe JM, Kouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant. 1995;15(1):145–8.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989;4(2):207–8.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Hashino S, Nozawa A, Izumiyama K, Yonezumi M, Chiba K, Kondo T, et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002;29(4):361–3.CrossRefPubMedGoogle Scholar
  69. 69.
    Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12(1):84–94.CrossRefPubMedGoogle Scholar
  70. 70.
    Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol. 2001;15(9):599–603.CrossRefPubMedGoogle Scholar
  71. 71.
    Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48(5):1001–26.CrossRefPubMedGoogle Scholar
  72. 72.
    Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2010;17(1):1–15.CrossRefPubMedGoogle Scholar
  73. 73.
    Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17(15):1927–38.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Giudice CL, Martinengo M, Pietrasanta P, Bocciardo L, Malavasi C, Rastelli S, et al. Occult hepatitis B virus infection: a case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation. Blood Transfus. 2008;6(1):46–50.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Chen GD, Gu JL, Qiu J, Chen LZ. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers. Transpl Infect Dis. 2013;15(3):300–5.CrossRefPubMedGoogle Scholar
  76. 76.
    Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl. 2004;10(3):356–62.CrossRefPubMedGoogle Scholar
  77. 77.
    Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479–86.CrossRefPubMedGoogle Scholar
  78. 78.
    Cardell K, Akerlind B, Sallberg M, Fryden A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis. 2008;198(3):299–304.CrossRefPubMedGoogle Scholar
  79. 79.
    Pin M, Compte MT, Angelet P, Gallego C, Gutierrez C, Martinez Vea A. Long-term evaluation of immune response to hepatitis B vaccine in 136 patients undergoing hemodialysis. Nefrologia. 2009;29(5):415–20.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Kramer ES, Hofmann C, Smith PG, Shiffman ML, Sterling RK. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci. 2009;54(9):2016–25.CrossRefPubMedGoogle Scholar
  81. 81.
    Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429–38.CrossRefPubMedGoogle Scholar
  82. 82.
    Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 8th ed. Philadelphia, PA: Elsevier; 2016. x, 836 pGoogle Scholar
  83. 83.
    Smith DB, Simmonds P, International Committee on the Taxonomy of Viruses Hepeviridae Study Group, Jameel S, Emerson SU, Harrison TJ, et al. Consensus proposals for classification of the family Hepeviridae. J Gen Virol. 2015;96(Pt 5):1191–2.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.CrossRefPubMedGoogle Scholar
  85. 85.
    Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14(1):1–21, viiCrossRefPubMedGoogle Scholar
  86. 86.
    Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5):408–14.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011;25(7):899–904.CrossRefPubMedGoogle Scholar
  88. 88.
    Williams JL, Cagle HH, Christensen CJ, Fox-Leyva LK, McMahon BJ. Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992. Transfusion. 2005;45(6):1020–6.CrossRefPubMedGoogle Scholar
  89. 89.
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8.CrossRefPubMedGoogle Scholar
  90. 90.
    Gonzalez-Grande R, Jimenez-Perez M, Gonzalez Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421–32.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401–12.CrossRefPubMedGoogle Scholar
  92. 92.
    Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, et al. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005;42(1):86–92.CrossRefPubMedGoogle Scholar
  93. 93.
    Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut. 1999;45(4):613–7.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Hughes RD, Wendon J, Gimson AE. Acute liver failure. Gut. 1991;32(Suppl):S86–91.CrossRefPubMedCentralGoogle Scholar
  95. 95.
    Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–31.CrossRefPubMedGoogle Scholar
  97. 97.
    Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 Pt 1):809–16.CrossRefPubMedGoogle Scholar
  98. 98.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.CrossRefPubMedGoogle Scholar
  99. 99.
    Giannini E, Mastracci L, Botta F, Romagnoli P, Fasoli A, Risso D, et al. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. Eur J Gastroenterol Hepatol. 2001;13(11):1355–61.CrossRefPubMedGoogle Scholar
  100. 100.
    Larson AM, Taylor SL, Bauermeister D, Rosoff L Jr, Kowdley KV. Pilot study of the relationship between histologic progression and hepatic iron concentration in chronic hepatitis C. J Clin Gastroenterol. 2003;37(5):406–11.CrossRefPubMedGoogle Scholar
  101. 101.
    Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75–85.CrossRefPubMedGoogle Scholar
  102. 102.
    Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003;38(3):307–14.CrossRefPubMedGoogle Scholar
  103. 103.
    Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51(4):655–66.CrossRefPubMedGoogle Scholar
  104. 104.
    Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745–59.CrossRefPubMedGoogle Scholar
  105. 105.
    Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22–6.CrossRefPubMedGoogle Scholar
  106. 106.
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41.CrossRefPubMedGoogle Scholar
  107. 107.
    Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32(3):344–55.CrossRefPubMedGoogle Scholar
  108. 108.
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–72.CrossRefPubMedGoogle Scholar
  109. 109.
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127(5):1372–80.CrossRefPubMedGoogle Scholar
  110. 110.
    El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4(1):5–10.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006;130(3):703–14.CrossRefPubMedGoogle Scholar
  112. 112.
    George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729–38.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127(10):875–81.CrossRefPubMedGoogle Scholar
  114. 114.
    Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52(1):132–41.CrossRefPubMedGoogle Scholar
  115. 115.
    Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51(6):2069–76.CrossRefPubMedGoogle Scholar
  117. 117.
    Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):932–7.CrossRefPubMedGoogle Scholar
  118. 118.
    Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38(3):322–7.CrossRefPubMedGoogle Scholar
  119. 119.
    Gonzalez SA, Trotter JF. The rise of the opioid epidemic and hepatitis C positive organs: a new era in liver transplantation. Hepatology. 2018;67(4):1600–8.CrossRefPubMedGoogle Scholar
  120. 120.
    Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–33.CrossRefPubMedGoogle Scholar
  121. 121.
    Coilly A, Roche B, Duclos-Vallee JC, Samuel D. Management of post transplant hepatitis C in the direct antiviral agents era. Hepatol Int. 2015;9(2):192–201.CrossRefPubMedGoogle Scholar
  122. 122.
    Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol. 2011;26(Suppl 1):96–101.CrossRefPubMedGoogle Scholar
  123. 123.
    Chan A, Patel K, Naggie S. Genotype 3 infection: the last stand of hepatitis C virus. Drugs. 2017;77(2):131–44.CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–54.CrossRefGoogle Scholar
  125. 125.
    Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol. 2014;20(32):11095–115.CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996;110(1):167–77.CrossRefPubMedGoogle Scholar
  127. 127.
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334(13):815–20.CrossRefPubMedGoogle Scholar
  128. 128.
    Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41(5):830–6.CrossRefPubMedGoogle Scholar
  129. 129.
    Watt KD, Laryea MA. Recurrent disease following liver transplantation. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff’s diseases of the liver. 11th ed. Philadelphia, PA: Wiley & Sons; 2012. p. 1152–66.Google Scholar
  130. 130.
    Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl. 2007;13(2):219–26.CrossRefPubMedGoogle Scholar
  131. 131.
    Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19(4):904–9.CrossRefPubMedGoogle Scholar
  132. 132.
    Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335–42.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52–61.CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55(1):4–13.CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis. 2004;19(3–4):357–81.CrossRefPubMedGoogle Scholar
  136. 136.
    Pischke S, Cornberg M, Manns MP. Hepatitis associated cryoglobulinemia. Internist (Berl). 2008;49(3):297–304.CrossRefGoogle Scholar
  137. 137.
    White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–44.CrossRefPubMedPubMedCentralGoogle Scholar
  138. 138.
    Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42(4):631–57.CrossRefPubMedGoogle Scholar
  139. 139.
    Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol. 1992;38(1):44–8.PubMedPubMedCentralGoogle Scholar
  140. 140.
    Chan TM, Lok AS, Cheng IK. Hepatitis C in renal transplant recipients. Transplantation. 1991;52(5):810–3.CrossRefPubMedGoogle Scholar
  141. 141.
    Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol. 1995;23(1):28–31.CrossRefPubMedGoogle Scholar
  142. 142.
    Arenas MD, Sanchez-Paya J, Barril G, Garcia-Valdecasas J, Gorriz JL, Soriano A, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant. 2005;20(6):1164–71.CrossRefPubMedGoogle Scholar
  143. 143.
    Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008;28(4):628–40.CrossRefPubMedGoogle Scholar
  144. 144.
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20(11–12):1271–7.CrossRefPubMedGoogle Scholar
  145. 145.
    Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5(1):139–44.CrossRefPubMedGoogle Scholar
  146. 146.
    Pham T. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. CANNT J. 2001;11(3):46.PubMedPubMedCentralGoogle Scholar
  147. 147.
    Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56(2):371–8.CrossRefPubMedGoogle Scholar
  148. 148.
    Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis. 1993;168(6):1343–8.CrossRefPubMedGoogle Scholar
  149. 149.
    Dalekos GN, Boumba DS, Katopodis K, Zervou E, Sferopoulos G, Elisaf M, et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant. 1998;13(7):1804–6.CrossRefPubMedGoogle Scholar
  150. 150.
    Kelley VA, Everett-Kitchens J, Brannon LE, Connor K, Martinez EJ, Pearson TC, et al. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation. 2002;74(10):1473–5.CrossRefPubMedGoogle Scholar
  151. 151.
    Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2(3):563–75.CrossRefPubMedGoogle Scholar
  152. 152.
    Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;(109):S1–99.Google Scholar
  153. 153.
    Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology. 2002;123(5):1494–9.CrossRefPubMedGoogle Scholar
  154. 154.
    Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant. 2005;5(7):1704–12.CrossRefPubMedGoogle Scholar
  155. 155.
    Delladetsima I, Psichogiou M, Sypsa V, Psimenou E, Kostakis A, Hatzakis A, et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis. 2006;47(2):309–16.CrossRefPubMedGoogle Scholar
  156. 156.
    Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29(4):608–14.CrossRefPubMedGoogle Scholar
  157. 157.
    Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation. 2005;79(9):1132–6.CrossRefPubMedGoogle Scholar
  158. 158.
    Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59(2):732–7.CrossRefPubMedGoogle Scholar
  159. 159.
    Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation. 1995;59(12):1676–82.CrossRefPubMedGoogle Scholar
  160. 160.
    Papafragkakis H, Fabrizi F, Martin P. Viral hepatitis in renal transplantation. Clin Nephrol. 2011;76(1):29–39.CrossRefPubMedGoogle Scholar
  161. 161.
    Morales JM, Campistol JM, Castellano G, Andres A, Colina F, Fuertes A, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 1995;47(1):236–40.CrossRefPubMedGoogle Scholar
  162. 162.
    Ali MK, Light JA, Barhyte DY, Sasaki TM, Currier CB Jr, Grandas O, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation. 1998;66(12):1694–7.CrossRefPubMedGoogle Scholar
  163. 163.
    Gupta G, Kang L, Yu JW, Limkemann AJ, Garcia V, Bandyopadhyay D, et al. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: analysis of United States national data. Clin Transpl. 2017;31(10)CrossRefGoogle Scholar
  164. 164.
    Fagiuoli S, Minniti F, Pevere S, Farinati F, Burra P, Livi U, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant. 2001;20(7):718–24.CrossRefPubMedGoogle Scholar
  165. 165.
    Cadranel JF, Di Martino V, Dorent R, Bernard B, Hoang C, Myara A, et al. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study. Transplantation. 2003;75(7):977–82.CrossRefPubMedGoogle Scholar
  166. 166.
    Lake KD, Smith CI, Milfred-La Forest SK, Pritzker MR, Emery RW. Outcomes of hepatitis C positive (HCV+) heart transplant recipients. Transplant Proc. 1997;29(1–2):581–2.CrossRefPubMedGoogle Scholar
  167. 167.
    Fong TL, Hou L, Hutchinson IV, Cicciarelli JC, Cho YW. Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation. 2009;88(9):1137–41.CrossRefPubMedGoogle Scholar
  168. 168.
    Lee I, Localio R, Brensinger CM, Blumberg EA, Lautenbach E, Gasink L, et al. Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant. 2011;30(11):1266–74.CrossRefPubMedPubMedCentralGoogle Scholar
  169. 169.
    Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2(5):443–7.CrossRefPubMedGoogle Scholar
  170. 170.
    Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B, Goormastic M, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology. 1999;30(5):1293–8.CrossRefPubMedGoogle Scholar
  171. 171.
    Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006;296(15):1843–50.CrossRefPubMedPubMedCentralGoogle Scholar
  172. 172.
    Trakroo S, Qureshi K. Successful treatment of chronic hepatitis C infection with direct-acting antivirals in a heart transplant recipient: a case report. Transplant Proc. 2015;47(7):2295–7.CrossRefPubMedGoogle Scholar
  173. 173.
    Fong TL, Cho YW, Hou L, Hutchinson IV, Barbers RG, Herrington CS. Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients. Transplantation. 2011;91(11):1293–6.CrossRefPubMedGoogle Scholar
  174. 174.
    Carreno MC, Piedad UG, Maite L, Andres V, Francisca P, Cesar B, et al. Hepatitis C virus infection after lung transplantation: dim prognosis. J Heart Lung Transplant. 2001;20(2):224.CrossRefPubMedGoogle Scholar
  175. 175.
    Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25(7):745–55.CrossRefPubMedGoogle Scholar
  176. 176.
    Carbone M, Lenci I, Baiocchi L. Prevention of hepatitis C recurrence after liver transplantation: an update. World J Gastrointest Pharmacol Ther. 2012;3(4):36–48.CrossRefPubMedPubMedCentralGoogle Scholar
  177. 177.
    Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, et al. Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol. 1994;88(2):392–4.CrossRefPubMedGoogle Scholar
  178. 178.
    Silvestri F, Barillari G, Fanin R, Pipan C, Falasca E, Salmaso F, et al. Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas. Haematologica. 1997;82(3):314–7.PubMedPubMedCentralGoogle Scholar
  179. 179.
    Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol. 2007;60(12):1378–83.CrossRefPubMedPubMedCentralGoogle Scholar
  180. 180.
    Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89–94.CrossRefPubMedGoogle Scholar
  181. 181.
    Levine AM, Shimodaira S, Lai MM. Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa. N Engl J Med. 2003;349(21):2078–9.CrossRefPubMedGoogle Scholar
  182. 182.
    Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med. 2012;51(19):2745–7.CrossRefPubMedGoogle Scholar
  183. 183.
    Locasciulli A, Testa M, Valsecchi MG, Bacigalupo A, Solinas S, Tomas JF, et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation. 1999;68(10):1486–91.CrossRefPubMedGoogle Scholar
  184. 184.
    Lyra AC, Brunt EM, Pincus S, Di Bisceglie AM. A 32-year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplant. Semin Liver Dis. 2002;22(1):103–8.CrossRefPubMedGoogle Scholar
  185. 185.
    Hwang YY, Liang RH. Hepatitis C in haematological patients. Hepat Res Treat. 2010;2010:961359.PubMedPubMedCentralGoogle Scholar
  186. 186.
    Ljungman P, Johansson N, Aschan J, Glaumann H, Lonnqvist B, Ringden O, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood. 1995;86(4):1614–8.PubMedPubMedCentralGoogle Scholar
  187. 187.
    Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103(5):1618–24.CrossRefPubMedGoogle Scholar
  188. 188.
    Peffault de Latour R, Asselah T, Levy V, Scieux C, Devergie A, Ribaud P, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2005;36(8):709–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jonathan Merola
    • 1
  • Alexander Z. Jow
    • 2
  • Samuel H. Sigal
    • 3
    Email author
  1. 1.Department of SurgeryYale School of Medicine, Yale-New Haven HospitalNew HavenUSA
  2. 2.Division of GastroenterologyMid-Atlantic Kaiser Permanente Medical GroupSpringfieldUSA
  3. 3.Division of Gastroenterology and Hepatology, Department of MedicineAlbert Einstein College of Medicine, Montefiore Medical CenterBronxUSA

Personalised recommendations